Kornimate/medical-research-clean huggingface dataset:
bk viremia after renal transplantation

Conditions: Terminal Renal Failure; BK Virus Infection

Summary: hypothesis: early detection, and treatment, of bk virus infection after kidney transplantation will prevent bk virus associated kidney transplant injury. bk virus associated nephropathy (bkvn) is estimated to cause a progressive kidney transplant injury in 1-10% of renal transplant recipients. diagnostic and monitoring strategies for bkvn is still being developed. detectable virus in the blood by polymerase change reaction-test (pcr) is predictive of bkvn. additionally, pcr provides a objective estimate of the degree of infection. if early detection and treatment of bk virus infection is effective in preventing subsequent kidney transplant injury has not been studied. however, renal injury and dysfunction develops late in the natural course of bkvn and it seems likely that screening in combination with early treatment would be beneficial for long-term transplant survival. there is no established treatment for bk virus infection. nevertheless, in kidney transplanted patients diagnosed with bk virus infection, immunosuppression is reduced to allow the patients own immune system to handle the virus. however, reduction of immunosuppression has not been associated with rejection. this indicate that these patients were over-immunosuppressed, predisposing them to bkvn. therefore, to compare the degree of immunosuppression in bkvn patients (over-immunosuppressed) to other patients (not over-immunosuppressed) could yield interesting information. one possibility would be to quantify these patients specific cellular immune response to bk virus but also to other viruses (t cell reactivity). leflunomide (arava) is an immunosuppressive drug, approved for the treatment of rheumatoid arthritis, and has been used in more than 300,000 patients worldwide. furthermore, leflunomide has been used safely in humans after clinical kidney and liver transplantation for more than 300 days. in addition to leflunomide's value in preventing rejection, it has been shown to exert inhibitory effects on different viruses. recently published pilot studies suggest that leflunomide treatment of patients with bkvn significantly reduces the amount of bk virus in blood and prevents recurrence of kidney transplant injury. at karolinska university hospital, leflunomide has been used for treatment of bkvn and, in some of the patients, renal function has stabilized and bk virus load has decreased significantly.


Eligibility criteria:
inclusion criteria: * all adult patients undergoing kidney transplantation at karolinska university hospital exclusion criteria: * absence of informed consent * allergy to leflunomide * pregnancy
pre procedural biomarkers might predict recurrent atrial fibrillation after catheter ablation

Conditions: Atrial Fibrillation

Summary: evaluation of the predictive value of serum levels of adipocytokines and primary phase reactant for recurrent atrial fibrillation (raf) after catheter ablation in 26 patients had persistent and 91 patients had paroxysmal af. during 12-m follow-up, 41 patients had raf (35%). patients had raf were significantly older, had significantly higher bmi, lower ejection fraction and wider maximal left atrial diameter (lad). serum hs-crp, il-6, tnf-α, visfatin, and adiponectin levels were significantly higher in patients developed. elevated serum levels of tnf-α, visfatin and adiponectin are a significant positive predictors for raf.

objectives: estimation of serum levels of visfatin, adiponectin, tumor necrosis factor-α (tnf-α), interleukin-6 (il-6) and high-sensitivity c-reactive protein (hs-crp) in patients had atrial fibrillation (af) resistant to medical treatment and assigned to catheter ablation (ca) to evaluate these biomarkers as predictors for recurrent af (raf). patients \& methods: 117 patients; 26 patients had persistent and 91 patients had paroxysmal af underwent had clinical and echographic evaluations and gave blood samples for elisa estimation of serum levels of studied cytokines. ca was performed through isolation of all pulmonary veins according to the stepwise procedure of ablation. patients were re-evaluated every three months till 12-m follow-up for post-procedural raf.

Eligibility criteria:
inclusion criteria: * symptomatic paroxysmal or persistent af that was resistant to medical acceptable daily dose therapy in patients who were free of exclusion criteria and accepted to sign the written fully informed consent to undergo ca and to give pre-procedural blood samples. exclusion criteria: * history of the presence of longstanding persistent or permanent af, * myocardial infarction, acute coronary syndrome (acs), * significant heart failure (nyha3), * dilated or hypertrophic cardiomyopathy, * left ventricular ejection fraction (lvef)\< 35%, congenital pathologies, * significant valvular heart disease, * pulmonary embolism, * venous thrombosis, * intracardiac thrombus or inability to take warfarin or other oral anticoagulants, * hepatic or renal insufficiency, * acute inflammatory states (sepsis, chronic obstructive pulmonary disease in acute phase), * cancer, * autoimmune pathologies.
integra: a vanguard study of health service delivery in a mobile health delivery unit

Conditions: HIV Infections; Drug Use; Opioid Use; Opioid-use Disorder

Summary: the purpose of this study is to determine the efficacy of using a mobile health delivery unit ("mobile unit") to deliver "one stop" integrated health services - particularly medication for opioid use disorder (moud) and medication for hiv treatment and prevention - to people who inject drugs (pwid) with opioid use disorder (oud) to improve uptake and use of moud, and uptake and use of antiretroviral therapy (art) or pre-exposure prophylaxis (prep).

the purpose of this study is to determine the efficacy of using a mobile health delivery unit ("mobile unit") to deliver "one stop" integrated health services - particularly medication for opioid use disorder (moud) and medication for hiv treatment and prevention - to people who inject drugs (pwid) with opioid use disorder (oud) to improve uptake and use of moud, and uptake and use of antiretroviral therapy (art) or pre-exposure prophylaxis (prep). the intervention arm receiving health services in the mobile unit will be supported by peer navigation. an active control arm will receive peer navigation to health services available at community-based agencies. impact (cost-effectiveness, mathematical modeling) and implementation factors (mixed methods to identify barriers and facilitators of the interventions) will contextualize findings from the efficacy analysis. the impact of the covid-19 epidemic in the study population will also be assessed.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * urine test positive for recent opioid use and with evidence of recent injection drug use ("track marks") * diagnosed with oud per diagnostic and statistical manual of mental disorders (dsm)-5 * able and willing to give informed consent * willing to start moud treatment * able to successfully complete an assessment of understanding * self-reported sharing injection equipment and/or condomless sex in the last three months with partners of hiv-positive or unknown status * able to provide adequate locator information * confirmed hiv status, as defined in the hptn 094 study specific procedures manual exclusion criteria: * urine testing that is not negative for methadone within 30 days prior to enrollment is exclusionary, unless verified hospital records show methadone received as a medication for hospitalization only during the screening period. a volunteer may provide a sample for urine testing more than once during the screening period in order to achieve a negative result. if this criterion cannot be met within 30 days from the start of screening, the individual will be considered a screen failure and the volunteer has up to two more screening chances to successfully complete the screening process again. * received moud in the 30 days prior to enrollment by self-report * co-enrollment in any other interventional study unless approved by the clinical management committee (cmc)

Keywords: prep moud pwid hiv art opioid use disorder
this present study can be used by clinicians who treat psychiatric patients: dentists might expect xerogenic side effects of specific psychiatric drugs which can affect dental treatment, and the results can help psychiatrist to choose the less xerogenic psychiatric medication

Conditions: Psychiatric Disorders; Xerostomia Due to Hyposecretion of Salivary Gland

Summary: the goal of this observational study is to learn about the effects of psychiatric drug therapies on intra- and extra-oral sicca symptoms and salivation. the main question that it aims to answer is: does taking psychiatric medication cause oral dryness and/or any changes on whole and minor saliva secretion? participants taking psychiatric medication answered a 16-question questionnare, and their saliva production was measured by periotron device and by spitting method.


Eligibility criteria:
inclusion criteria: in the psychiatric group, the inclusion criteria was taking specific psychiatric medications. exclusion criteria: in the control group the exclusion criteria was reporting any diseases and taking medicines.
effects of an act-based psychological treatment in patients with hypersexuality

Conditions: Compulsive Sexual Behavior; Hypersexuality

Summary: investigation of the efficacy of acceptance and commitment therapy (act) for the psychological treatment of hypersexuality.

after being informed about the study, all patients giving written informed consent will be assessed to determine eligibility for study entry. patients who meet eligibility requirements will receive psychological intervention consisting in an 8-session individual on line-delivered act-based treatment. the participants will be assessed through self-report instruments before and after treatment and at 3 months follow-up. the clinical trial will not include a control group.

Eligibility criteria:
inclusion criteria: * older than 18 years-old * spanish speaking * having had a sexual relationship in the last year * significant score on the hbi inventory (of 53 or more) * at least 6 months of problematic pornography use or sexual practices * clinically significant discomfort related to sexual practices * degree of interference in his/her life of sexual practices greater than or equal to 5 out of 10 * at least one failure in his attempts to change his sexual life * desire to improve/reduce excessive sexual behaviour exclusion criteria: * practicing meditation at least once a week in the last three months * receiving psychological or psychopharmacological treatment * intellectual disability * substance dependence (use not associated with sex) * personality disorder or other serious or chronic mental disorder diagnosed
bio clinical collection of urothelial carcinoma

Conditions: Urothelial Carcinoma; Bladder Cancer

Summary: the goal of this study is to collect tumor samples, urines, stool and blood from patients with urothelial carcinoma. these samples will be stored in a secure and confidential laboratory of the toulouse university hospital.

recent studies have shown that the bladder also harbors friendly bacteria that are collectively called the microbiome. while the effect of the bladder microbiome to health remains to be more clearly understood, an imbalance in the microbiome is associated with several urinary diseases including overactive bladder and bladder cancer. but whether the microbiome affects the outcome of bacille calmette et guérin (bcg)-immunotherapy or chemotherapy in bladder cancer is still not known. researchers at toulouse university hospital want to learn as much as possible about bladder cancer. one way to do so is by studying what is in your urines, blood, stool, saliva and in your tumor. patients, who will be agree to take part in this study, will have at least about one tablespoon of blood (as a residual of current biological analysis), 1 container of urines, stool and saliva collected before bladder resection. after transurethral bladder resection or radical cystectomy scheduled as part of the standard of care, some tumor samples might be collected either as fresh tissue or as paraffin embedded tissue and store in a secure and confidential laboratory at toulouse university hospital. the patient's follow up will be schedule as the standard of care and no additional visit will be required for the study. oncological outcome of each patient will be recorded up to 5 years this is an investigational study in which up to 500 patients will take part in the collection. all patients will be all enrolled at toulouse university hospital.

Eligibility criteria:
inclusion criteria: * adult \>18 years old * patient with suspected or diagnosed urothelial carcinoma * patients who are willing to consent for this protocol. exclusion criteria: * pregnant or breastfeeding patients * patients under 18 years old * patients under guardianship or curators * patients unable to sign a free and informed consent

Keywords: urothelial carcinoma neoplasm bladder cancer
the impact of opioids in fractures - a case control study

Conditions: Fractures

Summary: in this study, the risk of opioid medications on fractures in older adults is investigated. patients from the surgical department with fractures and control patients from the internal department of the same hospital are inquired with a standardized questionaire about demographic and clinical risk factors for fractures. osteoporotic fracture risk is assessed using quantitative ultrasound. an impact of recent opioid medications on fractures is hypothesised.


Eligibility criteria:
inclusion criteria for both groups: * age \> 60 years * written informed consent exclusion criteria for both groups: * malignant disease within the last 12 month * troubles with memory, dementia or parkinsons disease * other fractures within the last 6 month exclusion criteria for the fracture group: * alcoholised during the fall * fracture older than 14 days
teas for the treatment of pain in bone metastases of lung cancer

Conditions: Cancer Pain; Non Small Cell Lung Cancer; Bone Metastases; Acupuncture

Summary: this multicenter, prospective, randomized controlled research study aims to objectively evaluate the role of transcutaneous electrical acupoint stimulation (teas), which combines the theory of acupuncture with transcutaneous electrical nerve stimulation (tens) therapy, for the treatment of pain in patients with bone metastases from lung cancer.


Eligibility criteria:
inclusion criteria: * fulfilled the diagnostic criteria of non-small cell lung cancer and had a diagnosis of definite bone-metastatic-related pain. * potent opioid analgesics have been prescribed regularly. * bone protective agents (bisphosphonates or desumumab) have been used regularly. * expected survival ≥ 3 months with no obvious contraindication to opioid therapy. * stable vital signs and ecog-ps score ≤ 2 points; able to cooperate with researchers to complete relevant study evaluations. * signed informed consent. exclusion criteria: * definitively diagnosed with pain unrelated to lung cancer. * received local radiation therapy or surgery targeting bone metastases within 1 week before enrollment or will receive during the intervention period. the surgery including vertebroplasty, radioparticle implantation, neurological lesions, and other minimally invasive interventions. * venous thrombosis in the upper and lower extremities (below the elbow / knee joint), active cerebrovascular disease, severe cardiopulmonary dysfunction, or those with respiratory depression. * pacemaker implantation or metallic implants in vivo. * skin lesions at the acupoints, poor skin condition, or other situations that are not suitable for treatment with teas. * opioid hypersensitivity. * psychiatric disorders or severe cognitive deficits. * participating in other clinical trialists influencing the evaluation of the results of this study.

Keywords: transcutaneous electrical nerve stimulation transcutaneous electrical acupoint stimulation
the effect of psychological state on post spinal puncture headache and backache

Conditions: Depression, Anxiety

Summary: to investigate the effect of patient mood before spinal anesthesia on post spinal puncture headache and backache

before spinal anesthesia patients' anxiety and depression mood will recorded with beck anxiety and beck depression scale fifteen minute before spinal anesthesia.seven days after surgery post spinal puncture headache and backache will assess by a telephonic interview

Eligibility criteria:
inclusion criteria: * patient scehedule surgery under spinal anesthesia * between 18-80 years old exclusion criteria: * patients with psychiatric disorders
goal directed therapy versus standard care in lung resection surgery (gdt-thorax study).

Conditions: Goal Directed Therapy; Fluid Therapy

Summary: the primary aim of this study is to quantify and compare the hemodynamic control of cardiac index in patients who receive either goal-directed therapy or standard hemodynamic management in lung resection surgery

the investigators hypothesize that the percentage of the intraoperative time in which the cardiac index is equal or superior to 2.2 l/min/m2 is higher in goal directed therapy

Eligibility criteria:
inclusion criteria: * adults patients ( 18 years old) * written informed consent * elective lung resection surgery (open or thoracoscopic lung lobectomy) exclusion criteria: * severe obesity * moderate to severe aortic insufficiency * renal failure requiring hemodialysis * left ventricle ejection fraction less than 35 % * urgent surgery

Keywords: cardiac output perioperative care postoperative complications
electrode positions in cardioverting atrial fibrillation

Conditions: Atrial Fibrillation

Summary: atrial fibrillation is the most common heart rhythm disorder, and the incidence is rapidly increasing. cardioversion using an electrical shock (dc-cardioversion) is an important treatment to reduce symptoms and improve patient's quality-of-life. the treatment is performed by applying gel electrodes to the chest. cardioversion is not always successful, and it is unknown which electrode-position provides the optimal efficacy. this study aims to compare two electrode positions, which are in clinical use: anterior-posterior (left front and left back) versus anterior-lateral (right front and left side of the chest).


Eligibility criteria:
inclusion criteria: 1. atrial fibrillation (documented on an ecg-12) 2. able and willing to sign informed consent 3. age ≥ 18 years 4. anticoagulation according to guidelines (patients with atrial fibrillation for \>48 hours will be required to have a documented weekly international normalized ratio (inr) ≥2.0 (including within 48 hours of cardioversion) or treatment with non-vitamin k oral anticoagulant for three weeks or longer. alternatively, a transoesophageal echocardiogram documenting the absence of intracardiac thrombi is accepted and cardioversion can be performed on treatment with low molecular weight heparin). exclusion criteria: 1. implanted pacemaker and/or cardioverter defibrillator (icd) 2. prior enrollment in the trial 3. hemodynamically unstable atrial fibrillation 4. untreated hyperthyroidism 5. known or suspected pregnancy

Keywords: cardioversion electrode position
impact of low-fat and full-fat milk on lipids and cardiac function in patients with coronary artery disease

Conditions: Coronary Artery Disease

Summary: this trial aimed to investigate the effects of low-fat and full-fat milk on patients with coronary artery disease (cad).

the effects of low-fat and full-fat milk on lipid profiles and sphingolipid profiles in cad patients are not well understood. in addition, milk intake is at a low level in the chinese population compared with developed countries. therefore, we aimed to conduct a randomized controlled trial to investigate the effects of low-fat and full-fat milk on lipid profiles, sphingolipid profiles, and cardiac performance in chinese cad patients.

Eligibility criteria:
inclusion criteria: (1) patients with cad exclusion criteria: (1) patients \ 135mmol/l, creatinine \> 200umol/l), or chronic lung disease; (4) patients with a life expectancy ≤ 6 months due to bleeding tendency and hematological diseases, malignant tumors, and end-stage diseases; (5) patients with valvular heart disease or left ventricular aneurysm who needed simultaneous surgeries; (6) patients with cerebrovascular disease (cerebral infarction or cerebral hemorrhage within 6 months before enrollment); (7) patients who enrolled in other drug intervention trials; (8) patients who received emergency percutaneous coronary intervention (pci); and (9) patients who reported intolerance to lactose.
collecting recorded videos of colonoscopy and gastroscopy tests for the evaluation of the (me-apds).

Conditions: Colon Polyp

Summary: the study shall mainly help to better evaluate the performance the me-apds device and secondly it may help the development of additional future versions of the me-apds. primary endpoints * clear video of the colon or the stomach or the esophagus achieved during the test. * acceptable colon or gastro test performance according to the standards, criteria, and regulations of the medical center of the trial. secondary endpoints • a recorded video of at least 80% of the actual test duration.

primary objectives • to support the offline evaluation, in objective way, of the performance of the me-apds device by testing the sensitivity and specificity and additional statistical parameters of its results achieved from running it on the collected recorded videos of colonoscopy and gastroscopy tests of the general population. secondary objectives • some of the data might be used also for the development of future versions of the me-apds each subject will pass regular colonoscopy and/or gastroscopy test during which an external recording system connected to the secondary "video out" connector of the endoscopy processing device will record the video presented on the endoscopy device screen from the beginning of the test till its end. the standard off-the shelf recording device will be connected to the endoscopy device's connector by the testing physician or his/her assistant during the test's preparation phase. at the beginning of the test the testing physician or his/her assistant will press on recording start button, and at end of the test, the testing physician or his/her assistant will press on recording stop button. at the end of each week, the recorded video will be backed-up from the recording device to an external storage with two copies, one for record keeping of the main investigator, and one for the sponsoring entity. pathology and procedure reports without any identification details will sent to the sponsor with the recorded video.

Eligibility criteria:
inclusion criteria: subjects must meet all the - criteria related to regular colonoscopy and/or gastroscopy according to the standard of care at the gastroenterolgy department of the selected center, _in addition the following - criteria have to be met to be eligible for the study: 1. able to read, understand and provide written informed consent; 2. females or males - older than 18 years old exclusion criteria: any of the following colonoscopy/gastroscopy related exclusion criteria will exclude the subject from the study: * bleeding disorder or unacceptable risk of bleeding * terminal illness or life threatening malignancy

Keywords: polyps